Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ajanta PharmaBOM:532331 -0.69%95 Pretax Margin % is 27.48% as of Jun. 2026, which is 4% above its 10-year median of 26.35. GuruFocus rates BOM:532331 with a GF Score™ of 95/100 and a GF Value™ of ₹3,348.50 (Fairly Valued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Ajanta Pharma ranks better than 88.95% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Ajanta Pharma's Pre-Tax Income for the
three
months ended in Jun. 2026 was ₹4,468 Mil. Ajanta Pharma's Revenue for the
three
months ended in Jun. 2026 was ₹16,260 Mil. Therefore, Ajanta Pharma's pretax margin for the quarter that ended in Jun. 2026 was 27.48%.
The historical rank and industry rank for Ajanta Pharma's Pretax Margin % or its related term are showing as below:
BOM:532331'
s Pretax Margin % Range Over the Past 10 Years
Min: 20.1 Med: 26.35 Max: 33.82
Current: 25.85
BOM:532331's Pretax Margin % is ranked better than 88.95% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.21
vs BOM:532331: 25.85
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Ajanta Pharma Pretax Margin % Related Terms
Ajanta Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Ajanta Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ajanta Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Ajanta Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ajanta Pharma (BOM:532331) has a Pretax Margin % of 27.48% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ajanta Pharma and its competitors. This is near median its historical median of 26.35. Over the past decade, Ajanta Pharma's Pretax Margin % has ranged from 20.10 to 33.82. According to the industry distribution chart, Ajanta Pharma ranks #106 out of 959 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Ajanta Pharma's Pretax Margin % too high?
Ajanta Pharma's current Pretax Margin % of 27.48% is near median its 10-year median of 26.35. Over the past 10 years, this metric has ranged from a low of 20.10 to a high of 33.82. The Drug Manufacturers industry median Pretax Margin % is 7.21. Ajanta Pharma's value of 27.48% is 281.1% above this industry median. Based on the distribution chart, Ajanta Pharma ranks #106 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ajanta Pharma ranks #106 out of 959 companies for Pretax Margin %. This places Ajanta Pharma in the top 11% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.21. Ajanta Pharma's value of 27.48% is 281.1% above this benchmark. Historically, Ajanta Pharma's own Pretax Margin % has ranged from 20.10 to 33.82 over the past decade. While the company's 10-year median is 26.35 vs. the industry median of 7.21, Ajanta Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.21, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ajanta Pharma's current Pretax Margin % of 27.48% is 281.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ajanta Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ajanta Pharma's current Pretax Margin % is 27.48%, which is near median its own 10-year median of 26.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (BOM:532331) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,480.95 — trading 4% above its estimated fair value. The current Pretax Margin % is 27.48%, which is near median its 10-year median of 26.35 and 281.1% above the Drug Manufacturers industry median of 7.21. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Ajanta Pharma (BOM:532331), the current Pretax Margin % is 27.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ajanta Pharma (BOM:532331) Overvalued in 2026?
Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued.
The current stock price of ₹3,480.95 is trading 4% above its estimated GF Value™ of ₹3,348.50.
GuruFocus considers Ajanta Pharma to be Fairly Valued.
Key valuation signals for BOM:532331:
Pretax Margin %: 27.48% (near median its 10-year median of 26.35)
GF Value™: ₹3,348.50 vs. price of ₹3,480.95 (4% above fair value)
Industry Position: 281.1% above the Drug Manufacturers median (#106 of 959)
No single metric tells the full story. See the BOM:532331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score
Get the complete analysis for BOM:532331
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532331 has been successfully added to your 
